InvestorsHub Logo

biocqr

12/12/18 7:27 AM

#222750 RE: masterlongevity #220285

ACIU > AC Immune and Lilly Announce License and Collaboration Agreement

https://www.businesswire.com/news/home/20181212005145/en/AC-Immune-Lilly-Announce-License-Collaboration-Agreement

Under the terms of the agreement, AC Immune will receive an upfront payment of CHF80 million as well as $50 million in exchange for a note, convertible to equity at a premium. AC Immune is also eligible to receive CHF60 million in potential near-term development milestones, as well as other potential development, regulatory and commercial milestones up to approximately CHF1.7 billion, and tiered royalty payments in the low double digits.

AC Immune will conduct the initial Phase 1 development of the Morphomer tau aggregation inhibitors, while Lilly will fund and conduct further clinical development. Lilly will receive worldwide commercialization rights for the tau aggregation inhibitors in the area of Alzheimer’s disease. AC Immune has retained certain development rights in orphan indications and co-development and co-promotion options in certain indications outside AD.